CookiesThis site uses cookies to analyze site interaction in order to improve the quality of service and ensure smooth operation of the site. In more detail in Cookies policy
A specialized edition intended for medical institutions and doctors.
In addition to standard therapy including β-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (left ventricular ejection fraction ≤ 40 %) and clinical evidence of heart failure after recent myocardial infarction.
In addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 30%) (see the section ‘Pharmacodynamic properties’).
Release formThe tablet is indivisible
Temperature storage conditionsNot higher than 25 °С
DriversWith caution
DiabeticsAllowed
Release categoryPrescription medication
ChildrenContraindicated